Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05684731 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer

Study acronym: K19017-004
StatusUnknown
PhasePhase 1
Started2023-02-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 13, 2024 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06
Trial status changed: Recruiting → Unknown
2024-08-11
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Unknown
Study sitesdetails revised at 1 of 1 site
2023-01-05
Original filing
Tongji Hospital
197 trials monitored
See 2 trials at risk
Ovarian Cancer
1,239 trials monitored
See 74 trials at risk
The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend Phase 2 Dose (RP2D) of KM1 in the treatment of patients with recurrent or refractory ovarian cancer.
Trial Details
NCT Number NCT05684731
Lead Sponsor Tongji Hospital
Collaborators: Qilu Hospital of Shandong University, People's Hospital of Quzhou, Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd.
Conditions Ovarian Cancer
Enrollment 30 participants
Start Date 2023-02-01
Primary Completion 2025-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-13